BLTE Belite Bio, Inc
Financings ·
Belite Bio says its $402 million offering was completed with the overallotment option fully exercised. The same release reports a 2025 net loss of $77.6 million, up from $36.1 million, and cash of $352.9 million at year-end.
Belite Bio is selling 258,309 ADSs and warrants for the same number of ADSs at $58.07 each through Titan Partners Group LLC. The prospectus says the company has recorded net cash outflows from operations since inception.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $45.4 million | $29.9 million |
| Net income (loss) | -$77.6 million | -$36.1 million |
| Cash from operations | -$37.0 million | -$29.2 million |
| Cash and equivalents | $352.9 million | $31.7 million |
| Short-term investments | $4.5 million |
Our latest story on this, dated Mar 2, 2026: "Belite Bio says it completed a $402 million public offering of ADSs". The story links the filing or release it is based on. Read the story.
Belite Bio, Inc trades under the ticker BLTE on NASDAQ.
Belite Bio, Inc is listed on NASDAQ.
The SEC Central Index Key (CIK) for Belite Bio, Inc is 1889109. Its filings are on SEC EDGAR.
39,339,960 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-31.
Our directory records Belite Bio, Inc under United States.
Our directory classifies Belite Bio, Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Belite Bio, Inc is US07782B1044.
aibio.space lists Belite Bio, Inc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as E9.
Belite Bio, Inc reported a net loss of $77.6 million for the fiscal year ended Dec 31, 2025, and used $37.0 million of cash in operations, per its annual report to the SEC.
$45.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$352.9 million in cash at Dec 31, 2025, per its 20-F.
Our latest story on Belite Bio, dated Mar 2, 2026: "Belite Bio says it completed a $402 million public offering of ADSs". Belite Bio says its $402 million offering was completed with the overallotment option fully exercised. The same release reports a 2025 net loss of $77.6 million, up from $36.1 million, and cash of $352.9 million at year-end. Source.
SEC records list Belite Bio, Inc's filer category as: Large accelerated filer.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a financing. SEC Form 424B7. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio